AnaSpec Introduces Industry’s First and Only Anti-MOG ELISA Kits

June 16, 2007 – San Jose, CA

Drawing on its broad portfolio of MOG (35-55) and other multiple sclerosis (MS) experimental autoimmune encephalomyelitis (EAE)-related peptides, AnaSpec has just released its new line of SensoLyte™ Anti - MOG ELISA Kits - the industry’s first and only anti-MOG ELISA kits.

Myelin oligodendrocyte glycoprotein (MOG), a member of the immunoglobulin superfamily, is expressed exclusively in central nervous system myelin. Recent studies suggest that MOG may function in the completion, compaction, and maintenance of myelin in the central nervous system.1 Even though MOG physiological function is not entirely understood, studies have correlated the immune response of MOG to autoimmune mediated demyelination in several species.2 MOG is able to induce encephalitogenic T cell response, autoantibody response, and produce relapsing-remitting neurological disease with an extensive plaque-like demyelination.3 Autoantibody response to MOG (35-55) has been observed in multiple sclerosis (MS) patients and MOG (35-55)-induced experimental autoimmune encephalomyelitis (EAE) mice;4-10 however, the exact pathological role of anti-MOG (35-55) autoantibody is not known and is currently under vigorous investigation in the field.

AnaSpec’s SensoLyte™ family of anti-MOG (35-55) IgG Quantitative ELISA Kits (Mouse/rat) are designed to further the research of MS. These kits are optimized to detect anti-MOG (35-55) mouse/rat IgG and IgG subtypes. Using strips pre-coated with MOG (35-55) peptide and pre-blocked with BSA, the amount of anti-MOG IgG subtypes in serum or cerebrospinal fluid can be determined by ELISA and the absorbance read at 450 nm.

Fore more information visit http://www.anaspec.com/products/productcategory.asp?id=526

Company Info

AnaSpec, Inc. is a leading provider of integrated proteomics solutions to pharmaceutical, biotech, and academic research institutions throughout the world. With a vision for innovation through synergy, AnaSpec focuses on three core technologies: peptides, detection reagents (dyes, assay kits, & antibodies), and combinatorial chemistry. Established in 1993, AnaSpec's ISO9001:2000 certified headquarters and manufacturing facilities are located in San Jose, CA.

For more information, visit www.anaspec.com


References:
1. Tzako, AG. et al. Current Medcinal Chem. 12, 1569 (2005).
2. Johns, TQ. et al. J. Neurochem. 72, 1(1999).
3. Karpus, WJ. et al. Methods 29, 362 (2003).
4. Huntington, ND. et al. International Immunology 18, 10 1473(2006).
5. March, AK. et al. J. Neuroimmunology 135, 117 (2003).
6. Slavin, A. et al. 23, 109 (1998).
7. Ichikawa, M. et al. Cellular Immunology 191, 97 (1999).
8. Robinson, W. et al. Nat. Biotechnology 21, 1033 (2003).
9. Mayo S. et al. Clinical Immunology 118:219-228 (2006).